ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

Investing.com -- ImmunityBio, an immunotherapy company, saw its shares surge by up to 20%, marking the most significant intraday rise since October 28.

In November 2024, the JP Conte Family Foundation made a transformative $5 million gift to UCSF to establish two professorships in the Department of Neurology. These endowed positions, overseen by ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

Yellow Pages Limited  ("Yellow Pages" or the "Company"), a leading Canadian digital media and marketing company, is pleased ...

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...

BTIG Research began coverage on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday morning, Marketbeat reports. The firm issued a buy rating and a $6.00 price target on ...